Video

Dr. Plimack on Frontline Checkpoint Inhibitors in Bladder Cancer

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses checkpoint inhibitors in the frontline setting of bladder cancer.

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses checkpoint inhibitors in the frontline setting of bladder cancer.

There are currently 2 approved checkpoint inhibitors for the first-line treatment of patients with metastatic bladder cancer who are cisplatin ineligible—pembrolizumab (Keytruda) and atezolizumab (Tecentriq).

The results with either of these agents can be durable in this patient population, says Plimack, but there is currently no long-term follow-up data available.

Related Videos
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Tiago Biachi, MD, PhD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Alberto Montero, MD, MBA, CPHQ